Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rivaroxaban + Aspirin for CV Prevention

N Engl J Med; 2017 Oct 5; Eikelboom, et al

Patients with stable atherosclerotic vascular disease assigned to rivaroxaban plus aspirin had better cardiovascular (CV) outcomes and more major bleeding events than those taking aspirin alone; however, rivaroxaban alone did not result in better CV outcomes than aspirin alone and resulted in more major bleeding events. This according to a double-blind clinical trial that randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). Primary outcome was a composite of CV death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. Researchers found:

  • The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 vs 496 patients; HR, 0.76), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin groups (288 vs 170 patients; HR, 1.70).
  • There was no significant difference in intracranial or fatal bleeding between the 2 groups.
  • There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (HR, 0.82).
  • The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group.

Citation:

Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319-1330. doi:10.1056/NEJMoa1709118.

Commentary:

We know that the sudden development of a clot (thrombosis) on top of an existent atherosclerotic plaque is the most common cause of MI. For this reason, aspirin has been a standard addition to therapy in patients with coronary artery disease to decrease the risk of recurrent MI. Many additions to aspirin have been studied, including dual antiplatelet therapy and the use of anticoagulant therapy. For the most part, these additions have yielded no clear benefit, with some trials showing decreases in some of the thrombotic endpoints which were often offset by an increase in major bleeding, yielding no overall benefit above that of aspirin alone. This trial was stopped early by the safety monitoring board due to clear overall benefit of a combination of aspirin and low-dose of rivaroxaban, 2.5 mg bid. It should be noted that the dose where benefit was seen was one-quarter of the dose recommended for stroke prophylaxis for atrial fibrillation. While there was increased bleeding risk, there was no increase in intracranial bleeds or fatal bleeding. There was a net benefit and lower mortality in the low-dose rivaroxaban plus aspirin group compared to the aspirin group alone. The accompanying editorial for this study is worth a read.1 This study will certainly be discussed among guideline committee members and we await clear recommendations about its place in the treatment of patients with coronary artery disease. —Neil Skolnik, MD

  1. Braunwald E. An important step for thrombocardiology. N Engl J Med. 2017;377(14):1387-1388. doi:10.1056/NEJMe1710241.

This Week's Must Reads

Acellular Pertussis Vaccine Is Safe & Effective, JAMA Pediatr; 2018 Nov; Wood, Nolan, et al

Influenza and Pertussis Vaccination in Pregnancy, Vaccine; ePub 2018 Nov 3; Wilcox, Bottrell, et al

Influenza Vaccine Efficacy in High-Risk Patients, Vaccine; ePub 2018 Nov 9; Shang, Chung, et al

Childhood Vaccination Coverage Rates Compared, J Paediatr Child Health; ePub 2018 Nov 13; Baumann, et al

Measles Immunity After Vaccination in Children with HIV, Clin Infect Dis; ePub 2018 Nov 12; Mutsaerts, et al

Must Reads in Cardiology

CVD Events Prevented with New AHA BP Guideline, Circulation; ePub 2018 Nov 19; Bress, et al

PUFAs for Primary & Secondary CVD Prevention, Cochrane Library; ePub 2018 Nov 27; Abdelhamid, et al

Is Obesity Associated With Adverse CV Outcomes?, JAMA Netw Open; 2018 Nov 16; Riaz, et al

Cholesterol Guidelines Stress Lifetime Approach, Circulation; ePub 2018 Nov 10; Grundy, et al

Does Vitamin D Reduce Cancer & CVD Risk?, N Engl J Med; ePub 2018 Nov 10; Manson, et al